
======================================================================
PCR ASSAY DESIGN SUMMARY FOR KRAS G12D DETECTION
======================================================================

TARGET MUTATION:
  Gene: KRAS
  Mutation: G12D (Glycine to Aspartic Acid)
  Location: chr12:25209531
  Change: G>A
  Clinical Significance: Common oncogenic driver in colorectal cancer

PRIMER DESIGNS:
  1. Wildtype-Specific Forward:
     AGTAATCAACTGCATGCACCAAAAG
     Tm: 54.9°C, GC: 40.0%

  2. Mutant-Specific Forward (G12D):
     AGTAATCAACTGCATGCACCAAAAA
     Tm: 54.5°C, GC: 36.0%

  3. Common Reverse:
     CAGTGGAAGTTTTTTTTTCCTCTAA
     Tm: 50.5°C, GC: 32.0%

EXPECTED PCR PRODUCT:
  Size: 134 bp

PCR SIMULATION RESULTS:
  ✓ WT Primer + WT Template: AMPLIFIES (100%)
  ✗ WT Primer + Mutant Template: NO AMPLIFICATION (5%)
  ✗ Mutant Primer + WT Template: NO AMPLIFICATION (5%)
  ✓ Mutant Primer + Mutant Template: AMPLIFIES (100%)

RECOMMENDED PCR PROTOCOL:
  1. Annealing Temperature: 58-62°C (optimize based on primer Tm)
  2. Extension Time: 30 seconds (product ~134 bp)
  3. Cycles: 35-40 cycles
  4. Template DNA: 10-50 ng per reaction

  Two-Tube Assay:
    Tube 1: Wildtype-specific primer + Common reverse
    Tube 2: Mutant-specific primer + Common reverse

  Interpretation:
    - Both tubes positive: Heterozygous mutation (WT + Mutant)
    - Only Tube 1 positive: Wildtype only
    - Only Tube 2 positive: Homozygous mutation
    - Both tubes negative: PCR failure (check controls)

CLINICAL APPLICATION:
  - Screening for KRAS G12D in ctDNA from colorectal cancer patients
  - Monitoring mutation burden during anti-EGFR therapy
  - Detection limit: ~1-5% VAF with standard qPCR
  - For lower VAF (<1%), consider digital droplet PCR (ddPCR)

OUTPUT FILES GENERATED:
  1. KRAS_G12D_wildtype.fasta - Wildtype sequence
  2. KRAS_G12D_mutant.fasta - Mutant sequence
  3. KRAS_G12D_primers.csv - Primer information
  4. KRAS_G12D_pcr_simulation.png - Results visualization

NEXT STEPS:
  1. Order primers from IDT or other supplier
  2. Validate with positive control DNA (synthetic oligos)
  3. Optimize annealing temperature with gradient PCR
  4. Test on patient ctDNA samples
  5. Establish limit of detection with serial dilutions

======================================================================
